Skip to main content
Premium Trial:

Request an Annual Quote

Fulgent Genetics to Offer $22.5M in Stock

NEW YORK – Fulgent Genetics intends to sell $22.5 million in shares of its common stock, the firm said in a regulatory document on Friday.

Separately, the company said it entered an agreement with investment bank Piper Jaffray to sell $30 million of its shares from time to time. The $22.5 million offering disclosed in a prospectus filed last week with the US Securities and Exchange Commission is part of that deal. It said that proceeds will go toward working capital and general corporate purposes.

Fulgent did not price the offering.

Last month, Fulgent said it had plans to offer up to $75 million of its securities. The Temple City, California-based firm offers testing for hereditary genetic conditions to clinical and research customers and trades on the Nasdaq under ticker symbol "FLGT."

In afternoon trading, shares of Fulgent on the Nasdaq were down less than 4 percent at $11.00.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.